📢 The highlights of the Management Board meeting are now available.

Read more about
➡️the Agency’s additional responsibilities as part of its extended mandate
➡️the recent operational experience with the #clinicaltrials information system (#CTIS).

👉https://www.ema.europa.eu/en/news/ema-management-board-highlights-march-2023-meeting

🐦🔗: https://n.respublicae.eu/EMA_News/status/1636750775446536194

📢 From today, all initial clinical trial applications in the EU 🇪🇺 must be submitted via #CTIS!

All clinical trial sponsors will now use the same system and follow the same procedures to apply for the authorisation of a #clinicaltrial.

➡️ https://www.ema.europa.eu/en/news/use-clinical-trials-information-system-becomes-mandatory-new-clinical-trial-applications-eu

🐦🔗: https://n.respublicae.eu/EMA_News/status/1620367835217428481

On 18 January, EMA’s Management Board was provided with an update on recent improvements introduced in the Clinical Trials Information System (#CTIS) and progress made for its mandatory use from 31 January 2023.⏰🗓️

➡️https://www.ema.europa.eu/en/news/mandatory-use-ctis-31-january-2023-all-new-clinical-trial-applications

#EUClinicalTrials

🐦🔗: https://n.respublicae.eu/EMA_News/status/1616085679544344576

At its October meeting, our Management Board heard updates on topics including our extended mandate, our working parties and the Clinical Trials Information System. #CTIS
👉https://www.ema.europa.eu/en/news/ema-management-board-highlights-october-2022-meeting

🐦🔗: https://nitter.eu/EMA_News/status/1578405634139095047

RT @bfarm_de: BfArM President @Karl_Broich: Our aim is to improve the way #EUclinicaltrials are regulated to better support medical research + innovation. #CTIS is an important step to simplify and expedit the application process. But we want to go further: https://t.co/0p5wgHe2VR #ICTD2022

🐦🔗: https://nitter.eu/EMA_News/status/1527575848638984192